Analysts Set Rallybio Corporation (NASDAQ:RLYB) PT at $5.00

Rallybio Corporation (NASDAQ:RLYB) has earned a consensus recommendation of “Reduce” from the five analysts that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $5.00.

Several equities research analysts recently issued reports on RLYB shares. Wall Street Zen raised shares of Rallybio from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Rallybio in a report on Saturday, September 27th.

Rallybio Stock Up 10.4%

RLYB stock opened at $0.56 on Friday. The stock has a market capitalization of $23.60 million, a price-to-earnings ratio of -0.60 and a beta of -1.10. Rallybio has a 52-week low of $0.22 and a 52-week high of $1.24. The stock’s fifty day simple moving average is $0.56 and its 200-day simple moving average is $0.44.

Rallybio (NASDAQ:RLYB) last released its earnings results on Thursday, August 7th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.02. Rallybio had a negative return on equity of 71.66% and a negative net margin of 5,473.33%.The firm had revenue of $0.21 million during the quarter. As a group, analysts anticipate that Rallybio will post -1.34 earnings per share for the current fiscal year.

Rallybio Company Profile

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.